Invokana (active ingredient: canagliflozin) is a treatment for Type 2 diabetes that lowers blood sugar by causing the kidneys to remove sugar from the body through the urine. The drug, made by Janssen Pharmaceuticals (a division of Johnson & Johnson), was approved in March 2013 by the FDA as the first drug in a class called sodium-glucose cotransporter-2 (SGLT2) inhibitors. It is estimated that around 1.7 million prescriptions for SGLT2 inhibitors were dispensed in pharmacies nationwide between 2014 and 2015.
Since the approval of SGLT2 Inhibitors, the FDA has reported on a number of patients suffering from serious adverse health reactions after taking the drugs. These include ketoacidosis, urinary tract infections (urosepsis and pyelonephritis), and acute kidney injury requiring hospitalization/ER visits. Since 2015, the FDA has issued multiple warnings about these injuries, and has required manufacturers to add warnings of these risks to the labels for SGLT2 inhibitors.
To learn more about Invokana/SGLT2 inhibitors and recovering compensation for your injuries, click here.
Several lawsuits have been filed in the U.S. District Court for the Southern District of Illinois and the U.S. District Court for the Eastern District of California to recover damages from the the manufacturers of Invokana and other SGLT2 inhibitors for their failure to adequately warn patients of these risks.
SLGT2 inhibitors include:
Serious side effects of Invokana and other SGLT2 inhibitors include:
If you have suffered from one of these serious conditions after taking Invokana or other SGLT2 inhibitors, our experienced defective pharmaceutical lawyers at Kaiser Gornick LLP can help you explore your options for recovering compensation. We are a leading product liability litigation firm that has successfully recovered hundreds of millions of dollars for clients against big companies and pharmaceutical giants. Start your case on a no recovery, no fee basis.